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ational Prescription Patterns and Relationship With Outcomes
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OBJECTIVES We sought to determine patterns of aspirin use and the relationship between aspirin
prescription and outcomes in patients with coronary artery disease (CAD) and heart failure
(HF).
BACKGROUND Because of the potential for exacerbating hypertension or renal insufficiency and possible
interactions with angiotensin-converting enzyme (ACE) inhibitors, the use of aspirin for
secondary prevention of coronary events is controversial in patients with HF.
METHODS We studied a national sample of Medicare beneficiaries65 years old after hospitalization for
HF with CAD and without aspirin contraindications between April 1998 and June 2001. We
assessed factors associated with aspirin prescription and the relationship between aspirin and
outcomes in regression models accounting for differences in patient, physician, and hospital
characteristics and for clustering of patients by hospital.
RESULTS Of the 24,012 patients, 54% received aspirin. Treated patients had lower unadjusted rates of
death (31% vs. 39% for those not receiving aspirin, p  0.001). In multivariable analyses,
aspirin remained associated with a lower risk of death (risk ratio [RR] 0.94; 95% confidence
interval [CI] 0.90 to 0.99). This association was similar regardless of hypertension, renal
insufficiency, or treatment with ACE inhibitors (p for all interactions 0.2). Aspirin also was
associated with lower risks of death or all-cause readmission (RR 0.98; 95% CI 0.97 to 0.99)
and of death or readmission for HF (RR 0.98; 95% CI 0.96 to 0.99).
CONCLUSIONS Almost one-half of patients with CAD hospitalized for HF in the U.S. are not treated with
aspirin. This study found no evidence of harm from aspirin in this population and suggests
a treatment benefit. Withholding aspirin based upon theoretical concerns about adverse
effects appears to be unjustified. (J Am Coll Cardiol 2005;46:955–62) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.062American College of Cardiology Foundation
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espirin is an inexpensive and effective treatment for many
atients with coronary artery disease (CAD). Although
linical practice guidelines advocate the use of aspirin for
atients with acute coronary syndromes (1,2), previous
evascularization (3), and chronic angina (4), its use in
atients with CAD and concomitant heart failure is con-
roversial. Physiological data suggest the possibility of an
ntagonistic effect between aspirin and angiotensin-
onverting enzyme (ACE) inhibitors (5). Furthermore,
From the *Division of Cardiology, Department of Medicine, Denver Health
edical Center, Denver, Colorado; the †Divisions of Cardiology and ‡Geriatric
edicine, Department of Medicine, University of Colorado Health Sciences Center,
enver, Colorado; §Colorado Foundation for Medical Care, Aurora, Colorado;
Section of Cardiovascular Medicine, Department of Internal Medicine, and ¶Section
f Health Policy and Administration, Department of Epidemiology and Public
ealth, Yale University School of Medicine, New Haven, Connecticut; and #Center
or Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven,
onnecticut. Dr. Masoudi is supported by NIH/NIA Research Career Award
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athore was supported by NIH Medical Scientist Training Grant GM07205. Dr.
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IA/Hartford Foundation Fellowship in Geriatrics, and has received honoraria from
fizer, Merck, and Bristol-Myers Squibb. Dr. Havranek as received honoraria from
nd has been a consultant for Bristol-Myers Squibb. The analyses upon which this aspirin can exacerbate hypertension and renal insufficiency,
otentially worsening heart failure (6–8). Existing data
ssessing the effects of aspirin on outcomes in patients with
eart failure from post-hoc analyses of randomized trials
nd observational studies are conflicting (9–18).
Although patterns of aspirin prescription in patients with
rimary CAD diagnoses have been examined in detail
19–23), those in patients with CAD and heart failure are
ot well described. Current heart failure treatment guide-
ublication is based were performed under Contract Number 500-99-C001 entitled
Utilization and Quality Control Peer Review Organization for the State of
olorado,” sponsored by the Center for Medicare and Medicaid Services, Department
f Health and Human Services. The content of the publication does not necessarily
eflect the views or policies of the Department of Health and Human Services, nor
oes mention of trade names, commercial products, or organizations imply endorse-
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nd completeness of the ideas presented. This article is a direct result of the Health
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edicaid Services, which has encouraged identification of quality improvement
rojects from analysis of patterns of care, and therefore required no special funding on
he part of this contractor. Ideas and contributions to the author concerning
xperiences in engaging with issues presented are welcomed.Manuscript received April 13, 2004; revised manuscript received July 20, 2004,
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Aspirin in Coronary Disease and Heart Failure September 20, 2005:955–62ines, although noting the potential limitations of aspirin,
onsider the use of antiplatelet agents for patients with
nderlying CAD a level IIa recommendation (i.e., one for
hich the weight of evidence is in favor of use despite
onflicting evidence) (24). The lack of consistent supporting
vidence and a corresponding class I indication for the use
f aspirin in these patients may result in variable rates of use
f a potentially beneficial medication.
We therefore sought to study aspirin prescription in a
ontemporary national cohort of older Medicare beneficia-
ies with heart failure and coexisting CAD. Our goal was to
haracterize national patterns of aspirin use in this popula-
ion and to determine the relationship between aspirin
rescription and the outcomes of mortality and readmission
t one year. The study of this large high-risk cohort
epresents a unique opportunity to assess both the patterns
f use and the potential benefit of aspirin in patients with
oth conditions.
ETHODS
tudy sample. The patient cohort in this study is derived
rom the National Heart Care (NHC) Project, a Centers for
edicare and Medicaid Services project to improve the
uality of heart failure care for Medicare beneficiaries (25).
he project database contains detailed demographic and
linical data on 78,882 fee-for-service Medicare beneficia-
ies hospitalized with the principal discharge diagnosis of
eart failure between April 1998 and March 1999 or July
000 and June 2001, inclusive. Medicare administrative bills
or hospitalization were searched for International Classifi-
ation of Diseases, Ninth Revision, Clinical Modification
odes 428.x, 402.01, 402.11, 402.91, 404.01, 404.11, and
04.9 to identify hospitalizations primarily for heart failure.
ecords were excluded if the patient was transferred to
nother acute care facility, left against medical advice, or had
hronic renal failure requiring dialysis. After these selection
riteria were applied, as many as 800 records were selected
or abstraction from each state, Puerto Rico, and the
istrict of Columbia. In states in which fewer than the
argeted number of heart failure discharges occurred during
he sampling period, a complete census of discharges was
btained. In cases in which more than one hospitalization
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CI  confidence interval
GFR  glomerular filtration rate
LV  left ventricular
NHC  National Heart Care
MI  myocardial infarction
RR  risk ratio
SCr  serum creatinineor heart failure was identified for a particular patient, only ine of the discharges was selected randomly for inclusion in
he study cohort.
We restricted our study cohort to those subjects with
AD. Because this study was of medical therapy at hospital
ischarge, patients who died during the index hospitaliza-
ion were excluded (n  5,048). Because patients younger
han 65 years that are enrolled in Medicare qualify as the
esult of special circumstances (chronic disability or end-
tage renal disease), we limited the study cohort to subjects
ge 65 years and older. Patients with a contraindication to
spirin use were excluded from the analysis (n  7,516).
spirin was considered at least relatively contraindicated in
atients with hematocrit values 30%, platelet counts
100,000/ml, or with secondary diagnosis International
lassification of Diseases, Ninth Revision, Clinical Modi-
cation codes for “coagulation defects” (286.x), “gastroin-
estinal hemorrhage” (456.0 to 456.2, 459.0, 530.7, 530.8,
31.0-531.4, 531.6, 532.0 to 532.4, 532.6, 533.0 to 533.4,
33.6, 534.0 to 534.4, 534.6, 569.3, 578.x) or “purpura and
ther hemorrhagic conditions” (287.x). Finally, because this
tudy focused upon aspirin use and drug interactions specific
o aspirin, patients treated with warfarin or nonaspirin
ntiplatelet agents at hospital discharge (n  11,660),
egardless of aspirin prescription, were excluded. The final
nalysis sample contained 24,012 discharges.
ata. PATIENT CHARACTERISTICS. Identified charts were
orwarded to clinical data abstraction centers, where trained
edical record reviewers collected data for 195 variables.
bstracted elements included demographic characteristics,
ast cardiac and noncardiac history, patient characteristics
n hospital admission, laboratory values, and events during
he index hospitalization, including procedures. For the
urposes of quantifying renal function, the serum creatinine
SCr) closest to hospital discharge was used. Because serum
reatinine does not accurately reflect renal function in many
lderly patients, estimated glomerular filtration rate (GFR)
as calculated using the abbreviated Modification of Diet in
enal Disease Study Equation: estimated GFR  186 
SCr)1.154  (age)0.203  (0.742 if female)  (1.210 if
frican American) (26). Because 5% of the cohort had an
stimated GFR 89 ml/min/1.73 m2, this variable was
ategorized as 59 ml/min/1.73 m2 (National Kidney
oundation categories of normal-mild renal insufficiency),
0 to 59 ml/min/1.73 m2 (moderate renal insufficiency), and
30 ml/min/1.73 m2 (severe renal insufficiency).
HYSICIAN AND HOSPITAL CHARACTERISTICS. The NHC
ata were linked with the American Medical Association
hysician Masterfile (27,28) using the unique physician
dentification number of the attending physician, who was
efined as the clinician primarily responsible for the pa-
ient’s care during hospitalization (29). Hospital character-
stics were ascertained by linking with American Hospital
ssociation Annual Surveys (30,31). Dates of death weredentified with the Medicare Enrollment Database (32).
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September 20, 2005:955–62 Aspirin in Coronary Disease and Heart Failureeadmission data were ascertained using Medicare Part A
dministrative files.
UTCOME VARIABLES. To identify correlates of aspirin
rescription, we designated the outcome of interest as the
ocumentation of aspirin in the medication regimen at
ospital discharge, in either prescription or nonprescription
orms. For outcomes analyses, the primary outcome was
eath at one year. Secondary outcomes included the com-
osite of death or readmission for all causes and the
omposite of death or readmission for heart failure.
ollow-up of at least one year was available for all patients.
tatistical analysis. Bivariate comparisons between pa-
ients treated and not treated with aspirin were performed
ith chi-square tests for categorical variables and the Wil-
oxon rank sum test for continuous variables. Rates of
spirin prescription by state were calculated. All analyses
ere performed with probability weights, based upon the
nverse sampling fraction for each state, to obtain estimates
hat are representative of the total number of heart failure
dmissions nationwide during the sampling period.
To identify the patient and provider characteristics associ-
ted with aspirin, we constructed multivariable hierarchical
ogistic models accounting for the clustering of patients by
ospital (33). Variables with a univariate p 0.05 or variables
onsidered clinically important were candidates for the model.
inal parameters were estimated in a hierarchical model with
robability weights and a random intercept for hospital.
To assess the relationship between aspirin and outcomes,
e used hierarchical logistic regression models with the
vent within one year as the dependent variable. In addition
o a variable for aspirin treatment, patient level variables
demographics, cardiac comorbidities, noncardiac comor-
idities, left ventricular [LV] function, discharge treatment
ith ACE inhibitors, and discharge treatment with beta-
lockers), hospital characteristics, and physician character-
stics were tested. All statistically or clinically significant
ariables were retained in the final model. To assess for
eterogeneity in the effect of aspirin in clinically important
atient strata, we determined the significance of the inter-
ction among aspirin prescription and age, gender, the
resence or absence of hypertension, LV systolic dysfunc-
ion, estimated GFR, and the discharge prescription of
CE inhibitors and beta-blockers individually with the
nclusion of a cross-product term of aspirin treatment with
he stratification variables. To test for differences in the
elationship between ACE inhibitor prescription and mor-
ality according to aspirin treatment, we constructed strati-
ed models assessing the odds ratio for discharge prescrip-
ion of ACE inhibitors stratified by aspirin use.
Unadjusted rates and performed exploratory and descrip-
ive analyses were performed with the SAS version 8.2
tatistical software (SAS Institute, Cary, North Carolina).
he STATA version 7.0 (STATA Corp., College Station,
exas) was used for the mortality model to account for theample design and probability weights. Final model param- 0ters for the hierarchical model with probability weights for
spirin prescription were estimated in MLwiN version 1.1
Centre for Multilevel Modelling, Institute of Education,
niversity of London, London, United Kingdom). All odds
atios were converted to estimated risk ratios (RRs) (34).
ESULTS
atient characteristics. Of the NHC cohort, 24,012 pa-
ients satisfied the inclusion criteria for this study. The mean
ge of the study cohort was 79  8 years. Among all
atients in the study cohort, 13,049 (54%) were discharged
n aspirin. Patients receiving aspirin were younger, and
reater proportions were white and male compared with
hose not treated (Table 1). Compared to patients not
reated with aspirin, a greater proportion of patients treated
ad a history of myocardial infarction (MI) and/or coronary
evascularization; a higher prevalence of coexisting cardio-
ascular conditions, including hypertension and cerebrovas-
ular disease; and higher rates of treatment at discharge with
CE inhibitors and beta-blockers. A lower prevalence of
oncardiovascular comorbidity (e.g., obstructive lung dis-
ase or dementia) was present in patients treated with
spirin.
atterns of treatment. Marked variation in aspirin pre-
cription existed by state, with rates ranging from 31% to
0%. Patients with more severe CAD received aspirin more
requently as part of their discharge regimen: of those
ithout previous MI or revascularization, 45% were treated,
hereas those with previous MI, revascularization, or both
ere treated more frequently (54%, 55%, and 61%, respec-
ively, p for trend 0.001) (Fig. 1). However, the variation
n rates treatment by state across strata of CAD severity
emained marked.
In the multivariable analysis, MI, revascularization, or
oth and symptoms of angina were associated with higher
ikelihood of aspirin treatment (Table 2). Patients with
ypertension were slightly more likely to receive aspirin
RR 1.03; 95% confidence interval [CI] 1.00 to 1.06), but
hose with a lower estimated GFR were equally likely as
hose with higher estimated GFR to receive aspirin.
mong provider characteristics, discharge from teaching
ospitals and care by a cardiologist were associated with
greater likelihood of aspirin treatment. Processes of
are, including discharge prescriptions for ACE inhibi-
ors and beta-blockers, were also associated with a higher
ikelihood of aspirin treatment. Patients receiving care
rom cardiologist attending physicians and in teaching
ospitals were more likely to receive aspirin, whereas
hose receiving care in for-profit hospitals had a lower
djusted likelihood of being treated.
reatment and outcomes. Patients treated with aspirin
ad significantly lower crude mortality rates compared with
hose not treated (31% vs. 39%, p  0.001). Although rates
f readmission for all causes (78% vs. 78%, respectively, p
.8) or for heart failure (69% vs. 70%, p  0.4) were similar
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Aspirin in Coronary Disease and Heart Failure September 20, 2005:955–62etween the two groups, patients treated with aspirin had
ower rates of the composite of death and all cause-
eadmission (85% vs. 89%, p  0.001) and death and
eadmission for heart failure (79% vs. 83%, p  0.001) than
hose who were not treated.
After adjustment for age, gender, and clinical risk factors,
spirin prescription was associated with significantly lower
isks of death (RR 0.94; 95% CI 0.89 to 0.99) (Table 3).
his association did not differ significantly in strata of
atient age, gender, or the presence of hypertension, ele-
ated serum creatinine, LV systolic dysfunction, or ACE
nhibitor prescription (Table 3, p value for all interactions
0.5). Conversely, the association between ACE inhibitor
able 1. The Patient Population
Total
(n  24,01
emographics
Age, mean (SE) 79.4  0.0
Age categories, yrs
65–74 29%
75–84 43%
85 28%
Gender, female 58%
Race
Caucasian 84%
African American 12%
Other nonwhite 5%
Admitted from SNF 9%
oronary history
CAD without previous MI or revascularization 34%
Previous MI 27%
Previous revascularization 19%
Previous MI and revascularization 20%
ther medical history
Angina pectoris 26%
Hypertension 68%
Atrial fibrillation 20%
Stroke 17%
Chronic lung disease 36%
Diabetes mellitus 44%
Dementia 9%
Estimated GFR (ml/min/1.73 m2)
59 31%
30–59 53%
30 15%
V systolic function
Preserved 32%
Impaired 36%
Not documented 32%
ischarge medications
ACE inhibitors 53%
Beta-blockers 31%
Diuretics 85%
rovider characteristics
Teaching hospital 37%
For-profit hospital 13%
Cardiologist 23%
p values comparing patients not treated with aspirin and those treated with aspirin.
ACE angiotensin-converting enzyme; CAD coronary artery disease; GFR
ursing facility.rescription and mortality (in all patients RR 0.92; 95% CI f.87 to 0.96) did not differ between patients treated with
spirin (RR 0.92; 95% CI 0.85 to 0.99) and those not
reated (RR 0.91; 95% CI 0.85 to 0.98; p value for
nteraction  0.8).
In multivariable analyses of the secondary composite end
oints, the discharge prescription of aspirin was associated
ith lower risks of death or readmission for all causes (RR
.98; 95% CI 0.97 to 0.99) and for death or readmission for
eart failure (RR 0.98; 95% CI 0.96 to 0.99).
ISCUSSION
n this national cohort of patients hospitalized with heart
Not Treated
With Aspirin
(n  10,963)
Treated
With Aspirin
(n  13,049)
p
Value*
79.8  0.098 78.9  0.012 0.001
0.001
27% 31%
44% 43%
29% 26%
60% 56% 0.001
0.001
83% 84%
11% 12%
5% 5%
12% 7% 0.001
0.001
40% 29%
26% 28%
18% 20%
16% 23%
23% 29% 0.001
66% 70% 0.001
22% 18% 0.001
17% 17% 0.99
39% 34% 0.001
41% 42% 0.49
10% 8% 0.001
0.40
32% 31%
53% 54%
15% 15%
0.001
31% 34%
32% 39%
37% 28%
46% 60% 0.001
23% 38% 0.001
79% 91% 0.001
34% 40% 0.001
15% 11% 0.001
20% 26% 0.001
ular filtration rate; LV left ventricular; MImyocardial infarction; SNF skilled2)
67ailure and CAD, 48% did not receive aspirin at hospital
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September 20, 2005:955–62 Aspirin in Coronary Disease and Heart Failureischarge, and treatment rates varied markedly by state.
lthough rates of prescription were higher in those with
revious MI, revascularization, or angina, 40% of patients
ith these important sequelae of CAD were not treated.
igure 1. Weighted median national rates and ranges of state rates of asp
oronary artery disease (CAD) severity in the U.S., 1998 to 2001 (p value fo
able 2. Factors Associated with Aspirin Prescription at
ospital Discharge
RR (95% CI)
emographics
Age, yrs
65–74 1.00 (ref.)
75–84 0.99 (0.96–1.01)
85 0.96 (0.93–1.00)
Female gender 0.96 (0.94–0.99)
Nonwhite race 0.98 (0.94–1.02)
oronary history*
CAD without previous MI or revascularization 1.00 (ref.)
Previous MI 1.15 (1.11–1.19)
Previous revascularization 1.18 (1.13–1.22)
Previous MI and revascularization 1.29 (1.24–1.33)
ther medical history
Angina pectoris* 1.15 (1.12–1.18)
Hypertension* 1.03 (1.00–1.06)
Atrial fibrillation* 1.04 (1.01–1.06)
Stroke 1.00 (0.97–1.04)
Diabetes mellitus 0.97 (0.95–1.00)
GFR (ml/min/1.73 m2)
59 1.00 (ref.)
30–59 1.03 (1.00–1.06)
30 1.00 (0.96–1.04)
V systolic function*
Preserved 1.00 (ref.)
Impaired 1.02 (0.99–1.05)
Not documented 0.88 (0.85–0.91)
ischarge medications
ACE inhibitor* 1.27 (1.24–1.30)
Beta-blocker* 1.32 (1.29–1.35)
rovider characteristics
Teaching hospital* 1.06 (1.03–1.10)
For-profit hospital* 0.88 (0.83–0.93)
Cardiologist attending* 1.16 (1.12–1.19)
Statistically significant correlation in the multivariable model (p  0.05).
CAD  coronary artery disease; ref.  referent group; RR  risk ratio; other
bbreviations as in Table 1.
*spirin treatment was associated with a reduction in the risk
f death that was consistent regardless of the presence or
bsence of hypertension, elevated serum creatinine, or co-
rescription of ACE inhibitors. Furthermore, aspirin did
ot attenuate the benefit of ACE inhibitors. These results
uggest that current patterns of practice may deprive many
atients with both CAD and heart failure from important
enefits from the use of an inexpensive drug.
The patterns of use observed in this study provide
ossible explanations for the factors motivating treatment
ith aspirin. Although patients with previous serious coro-
rescription for Medicare beneficiaries with heart failure as a function of
d across categories of CAD severity0.001). MImyocardial infarction.
able 3. Risk Ratios for One-Year Mortality Associated With
spirin Treatment in Subgroups
Adjusted RR (95% CI)*
ll patients 0.94 (0.89–0.99)
ge group, yrs
65–74 0.96 (0.85–1.07)
74–84 0.91 (0.85–0.99)
85 0.94 (0.86–1.01)
ender
Male 0.95 (0.87–1.02)
Female 0.93 (0.86–1.00)
ypertension
No 0.89 (0.81–0.96)
Yes 0.97 (0.90–1.03)
stimated GFR (ml/min/1.73 m2)
59 0.99 (0.89–1.09)
30–59 0.92 (0.85–0.99)
30 0.91 (0.81–1.00)
eft ventricular systolic function
Preserved 1.01 (0.88–1.15)
Impaired 0.92 (0.84–1.00)
Not documented 0.96 (0.88–1.03)
CE inhibitor treatment
No 0.93 (0.87–1.00)
Yes 0.94 (0.87–1.01)
eta-blocker
No 0.95 (0.89–1.01)
Yes 0.87 (0.78–0.99)p  0.05 for interaction between aspirin prescription and all subgroups.
Abbreviations as in Tables 1 and 2.
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Aspirin in Coronary Disease and Heart Failure September 20, 2005:955–62ary events and those with symptomatic CAD were more
ikely to receive aspirin, overall rates of use were low
ompared with other studies of populations with the pri-
ary diagnosis of CAD, perhaps in part because many of
he patient’s presentations were dominated by heart failure
19,20,22,23). Aspirin prescription was positively correlated
ith ACE-inhibitor treatment, implying that concerns
bout drug interactions did not entirely explain treatment
ecisions. Additionally, both the prescription of beta block-
rs and the documentation of LV function—guideline-
ecommended processes of care for patients with CAD and
eart failure, respectively (4,24)—were associated with
igher rates of aspirin prescription.
Although aspirin is an inexpensive and effective treat-
ent in reducing death and events in a broad range of
atients with CAD, its use in patients with heart failure
as been the center of controversy (35–38). Aspirin and
ther nonsteroidal anti-inflammatory agents may antag-
nize the vasodilator effects of ACE inhibitors (5),
xacerbate hypertension, decrease GFR (6,7), and atten-
ate the effects of diuretics (8), all of which could be
articularly detrimental in patients with heart failure.
urthermore, by causing renal insufficiency, aspirin may
imit the possibility of achieving optimal doses of ACE
nhibitors in some patients. In this study, however, no
vidence was found that hypertension or renal insuffi-
iency contributed significantly to the decision to pre-
cribe aspirin in patients with heart failure.
Among patients with heart failure, CAD is common
25,39), and vascular events are a common cause of death
n patients with CAD and concomitant heart failure (40).
espite the preponderance of CAD, the use of aspirin in
atients with heart failure has not been clarified by the
xisting evidence. Post-hoc subgroup analyses of ran-
omized clinical trials, many of which assess patients
fter acute MI, have provided mixed results (9 –14).
bservational studies of cohorts with heart failure with
AD have also produced conflicting data in relatively
mall samples of patients (15–18). This investigation,
hich is the largest observational study of the topic to
ate in a nationally representative cohort of patients with
eart failure in the context of contemporary patterns of
reatment, suggests no evidence of harm from aspirin use
nd the possibility of important benefits in this patient
opulation.
The relative risk reduction for mortality associated
ith aspirin prescription in this study (6% with confi-
ence intervals ranging from 1% to 10%) is lower than
hat reported by other studies of aspirin as secondary
revention in other high-risk populations such as those
fter acute MI, unstable angina, or stroke (41– 44).
ecause the primary benefit of aspirin is likely by the
eduction of vascular events, the risk reduction in death
rom vascular causes in patients with multiple types of
omorbidity may be diluted by competing mortality from
eart failure and noncardiovascular causes. Because we pere not able to ascertain the causes of death in this
ohort, we could not determine the effects of aspirin on
ascular death. Nevertheless, even a smaller risk reduc-
ion could have important implications for high-risk
atients.
Current guidelines, although acknowledging the theo-
etical possibility of an antagonistic interaction between
spirin and ACE inhibitors, classify antiplatelet treat-
ent in patients with heart failure and concomitant
AD a level IIa recommendation (a condition for which
here is conflicting evidence about efficacy but where the
eight of evidence is in favor of efficacy) (24). The
ncertainty surrounding the benefit of aspirin in patients
ith heart failure and the lack of a class I recommenda-
ion may explain some of the marked variation in
rescription patterns described in this study. Our data
upport the use of aspirin in patients with heart failure
nd CAD, including those treated with ACE inhibitors.
tudy limitations. Several issues merit consideration in
he interpretation of these results. Because this study was
bservational, it remains possible that unmeasured vari-
tion among patients could confound the results. How-
ver, we adjusted for a wide range of differences in
atients, providers, and other medical therapy in our
nalysis and accounted for the clustering of patients at
he hospital level. Additionally, we restricted the cohort
o patients without contraindications to aspirin prescrip-
ion, reducing the likelihood of confounding by indica-
ion. Our study suggests aspirin has clinically important
enefit in this population and no indication of harm.
lthough randomized trials are the ideal means of
ssessing this question, placebo-controlled trials of ade-
uate size studying aspirin in patients with CAD and
eart failure are unlikely because of concerns of with-
olding aspirin from such patients.
We were not able to assess the use of aspirin during the
ollow-up period. Thus, some of the patients treated with
spirin or ACE inhibitors at discharge may not have been
reated during follow-up and, conversely, these medica-
ions might have been initiated later in those initially not
reated. Classifying patients based on the discharge
edications would have biased our results to the null.
ecause dosing information was not available, we were
ot able to assess the relationship between aspirin doses
nd outcomes in this study. This study population
ncludes only older fee-for-service Medicare beneficiaries
ospitalized primarily for heart failure. Thus, although it
ay not be appropriate to generalize the findings of this
tudy to the entire elderly U.S. population with heart
ailure, we have examined a nationally representative and
mportant subset of this population that suffers a sub-
tantial burden of morbidity and mortality. Furthermore,
his cohort is likely more representative of the population
ith heart failure than randomized trials populations
ith respect to age, gender, racial, and comorbidity
rofile.
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eart failure and CAD varies markedly in the U.S., and
early half such patients are not treated after discharge
or hospitalization for heart failure. Aspirin treatment
as not associated with an increased risk of mortality
r readmission but was associated with lower risk of
dverse outcomes, even in patients with hypertension or
enal dysfunction, and those treated with ACE inhibi-
ors. Furthermore, there was no evidence that aspirin
ttenuates the benefits of ACE inhibitors. Withholding
his inexpensive treatment may deprive patients with
AD and concomitant heart failure of important clinical
enefits.
eprint requests and correspondence: Dr. Frederick A. Ma-
oudi, Division of Cardiology MC 0960, Denver Health Medical
enter, 777 Bannock Street, Denver, Colorado 80204. E-mail:
red.masoudi@uchsc.edu.
EFERENCES
1. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
guidelines for the management of patients with acute myocardial
infarction. J Am Coll Cardiol 1999;34:890–911.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines
for the management of patients with unstable angina and non–ST-
segment elevation myocardial infarction. J Am Coll Cardiol 2000;36:
970–1062.
3. Smith SC Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines for
percutaneous coronary intervention (revision of the 1993 PTCA
guidelines)—executive summary. Circulation 2001;103:3019–41.
4. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM
guidelines for the management of patients with chronic stable angina.
J Am Coll Cardiol 1999;33:2092–197.
5. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator
effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol
1992;20:1549–55.
6. Kimberly RP, Plotz PH. Aspirin-induced depression of renal function.
N Engl J Med 1977;296:418–24.
7. Muther RS, Potter DM, Bennett WM. Aspirin-induced depression of
glomerular filtration rate in normal humans: role of sodium balance.
Ann Intern Med 1981;94:317–21.
8. Koopmans PP, Thien T, Gribnau FW. Influence of non-steroidal
anti-inflammatory drugs on diuretic treatment of mild to moderate
essential hypertension. Br Med J Clin Res Ed 1984;289:1492–4.
9. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and
aspirin on mortality after acute myocardial infarction: subgroup anal-
ysis of the Cooperative New Scandinavian Enalapril Survival Study II
(CONSENSUS II). Am J Cardiol 1997;79:115–9.
0. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ,
Konstam MA. Antiplatelet agents and survival: a cohort analysis from
the Studies Of Left Ventricular Dysfunction (SOLVD) trial. J Am
Coll Cardiol 1998;31:419–25.
1. Oosterga M, Anthonio RL, De Kam PJ, Kingma JH, Crijns HJ, Van
Gilst WH. Effects of aspirin on angiotensin-converting enzyme
inhibition and left ventricular dilation one year after acute myocardial
infarction. Am J Cardiol 1998;81:1178–81.
2. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS.
Evaluation of the effects of aspirin combined with angiotensin-
converting enzyme inhibitors in patients with coronary artery disease.
Am J Med 2000;109:371–7.
3. Latini R, Santoro E, Masson S, et al. Aspirin does not interact with
ACE inhibitors when both are given early after acute myocardial
infarction: results of the GISSI-3 trial. Heart Disease 2000;2:185–90.
4. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with
angiotensin-converting-enzyme inhibitors in the presence or absence
of aspirin: a systematic review. Lancet 2002;360:1037–43.
35. Krumholz HM, Chen YT, Radford MJ. Aspirin and the treatment of
heart failure in the elderly. Arch Intern Med 2001;161:577–82.
6. Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction
with angiotensin-converting enzyme inhibitors does not worsen long-
term survival in heart failure. Int J Cardiol 2003;88:207–14.
7. Aumegeat V, Lamblin N, de Groote P, et al. Aspirin does not
adversely affect survival in patients with stable congestive heart failure
treated with angiotensin-converting enzyme inhibitors. Chest 2003;
124:1250–8.
8. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD.
Aspirin-angiotensin-converting enzyme inhibitor coadministration
and mortality in patients with heart failure: a dose-related adverse
effect of aspirin. Arch Intern Med 2003;163:1574–9.
9. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin in the
treatment of acute myocardial infarction in elderly Medicare
beneficiaries. Patterns of use and outcomes. Circulation 1995;92:
2841–7.
0. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for second-
ary prevention after acute myocardial infarction in the elderly: pre-
scribed use and outcomes. Ann Intern Med 1996;124:292–8.
1. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality
of care for Medicare patients with acute myocardial infarction: results
from the Cooperative Cardiovascular Project. JAMA 1998;279:
1351–7.
2. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care
delivered to Medicare beneficiaries: a profile at state and national
levels. JAMA 2000;284:1670–6.
3. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care
delivered to Medicare beneficiaries, 1998–1999 to 2000–2001. JAMA
2003;289:305–12.
4. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the
evaluation and management of chronic heart failure in the adult:
executive summary. J Am Coll Cardiol 2001;38:2101–13.
5. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL,
Krumholz HM. Spectrum of heart failure in older patients: results
from the National Heart Failure project. Am Heart J 2002;143:
412–7.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002;39:S1–S266.
7. Kenward K. The scope of the data available in the AMA’s Physician
Masterfile. Am J Public Health 1996;86:1481–2.
8. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C,
Warren L. Linking physician characteristics and Medicare claims data:
issues in data availability, quality, and measurement. Med Care
2002;40 Suppl 8:IV82–95.
9. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes.
2nd edition. Chicago, IL: Health Administration Press, 1997.
0. American Hospital Association. The AHA Annual Survey Database:
Fiscal Year 1998 Documentation. Chicago, IL: Health Forum, AHA,
1999.
1. American Hospital Association. The AHA Annual Survey Database:
Fiscal Year 2000 Documentation. Chicago, IL: Health Forum, AHA,
2001.
2. Fleming C, Fisher ES, Chang CH, Bubolz TA, Malenka DJ.
Studying outcomes and hospital utilization in the elderly. The advan-
tages of a merged data base for Medicare and Veterans Affairs
hospitals. Med Care 1992;30:377–91.
3. Goldstein H. Multilevel Statistical Models. 2nd edition. London:
Institute of Education, Multilevel Models Project, 1999.
4. Zhang J, Yu KF. What’s the relative risk? A method of correcting the
odds ratio in cohort studies of common outcomes. JAMA 1998;280:
1690–1.
5. Teerlink JR, Massie BM. The interaction of ACE inhibitors and
aspirin in heart failure: torn between two lovers. Am Heart J
1999;138:193–7.
6. Hall D. Controversies in heart failure. Are beneficial effects of
angiotensin-converting enzyme inhibitors attenuated by aspirin in
patients with heart failure? Cardiol Clin 2001;19:597–603.
7. Cleland JG, Alamgir F, Nikitin NP, Clark AL, Norell M. What is the
optimal medical management of ischemic heart failure? Prog Cardio-
vasc Dis 2001;43:433–55.8. Konstam MA. Aspirin and heart failure: square evidence meets a
round patient. Congest Heart Fail 2003;9:203–5.
34
4
4
4
4
A
F
962 Masoudi et al. JACC Vol. 46, No. 6, 2005
Aspirin in Coronary Disease and Heart Failure September 20, 2005:955–629. American Heart Association. Heart and Stroke Statistics—2003
Update. Dallas, TX: American Heart Association, 2002.
0. Cleland JG, Thygesen K, Uretsky BF, et al. Cardiovascular critical
event pathways for the progression of heart failure; a report from the
ATLAS study. Eur Heart J 2001;22:1601–12.
1. ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomized trial of intravenous streptokinase, oral aspirin,
both, or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. J Am Coll Cardiol 1988;12:3A–13A.
2. Antiplatelet Trialists’ Collaboration. Collaborative overview of ran-
domised trials of antiplatelet therapy—I: prevention of death, myo-
cardial infarction, and stroke by prolonged antiplatelet therapy in
various categories of patients. BMJ 1994;308:81–106. s3. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in
unstable angina. Results of a Canadian multicenter trial. N Engl J Med
1985;313:1369–75.
4. Lewis HD Jr., Davis JW, Archibald DG, et al. Protective effects of
aspirin against acute myocardial infarction and death in men with
unstable angina. Results of a Veterans Administration Cooperative
Study. N Engl J Med 1983;309:396–403.
PPENDIX
or the candidate variables for the adjusted models, please
ee the online version of this article.
